Advertisement
Screener

Standard BioTools Inc. (LAB) Debt / Equity

STANDARD BIOTOOLS INC. Debt/Equity Ratio

The debt/equity ratio shows how much a company has borrowed for every dollar its shareholders have put in. It is long-term debt, both the part due within a year and the rest, divided by shareholder equity, shown as a multiple with both amounts in the table. A higher ratio means the company relies more on borrowed money than on shareholder capital. Because equity shrinks through buybacks or losses, the ratio can rise even when debt is unchanged, and it has no meaning when equity is negative. Quarterly points use quarter-end balances; annual points use fiscal-year-end balances.

  • STANDARD BIOTOOLS INC. debt/equity ratio for the quarter ending 2012-12-31 was 0, a 100.00% decline year-over-year.
  • STANDARD BIOTOOLS INC. debt/equity ratio for the quarter ending 2012-09-30 was 0, a 100.00% decline year-over-year.
  • STANDARD BIOTOOLS INC. debt/equity ratio for the quarter ending 2012-06-30 was 0.06, a 72.31% decline year-over-year.
  • STANDARD BIOTOOLS INC. debt/equity ratio for the quarter ending 2011-12-31 was 0.18, a change of 0.26 year-over-year.
  • STANDARD BIOTOOLS INC. debt/equity ratio for fiscal 2012 was 0, a 100.00% decline from fiscal 2011.
  • STANDARD BIOTOOLS INC. debt/equity ratio for fiscal 2011 was 0.18, a change of 0.26 from fiscal 2010.
  • STANDARD BIOTOOLS INC. debt/equity ratio for fiscal 2010 was -0.08.
Available history
2010-12-31 to 2012-12-31
Data captured

Historical Debt/Equity Ratio

DateDebt/Equity RatioLong-term debtShareholder equity
2012-12-310$0.00$100.66M
2012-09-300$0.00$102.66M
2012-06-300.06$2.83M$48.92M
2011-12-310.18$10.14M$56.9M
2011-09-300.2$11.59M$59.15M
2011-06-300.21$13.01M$62.31M
2010-12-31-0.08$14.7M-$189.17M

Annual Debt/Equity Ratio

DateDebt/Equity RatioLong-term debtShareholder equity
2012-12-310$0.00$100.66M
2011-12-310.18$10.14M$56.9M
2010-12-31-0.08$14.7M-$189.17M

Similar stocks

Stock NameCountryMarket CapPE Ratio
ROCKET PHARMACEUTICALS, INC. (RCKT)United States$0.296B-21.78
Vanda Pharmaceuticals Inc. (VNDA)United States$0.302B-1.35
Fulcrum Therapeutics, Inc. (FULC)United States$0.289B-3.28
Contineum Therapeutics, Inc. (CTNM)United States$0.289B-4.40
GT Biopharma, Inc. (GTBP)United States$0.309B-4.58
Perspective Therapeutics, Inc. (CATX)United States$0.284B-3.34
Upstream Bio, Inc. (UPB)United States$0.284B-2.42
ABEONA THERAPEUTICS INC. (ABEO)United States$0.312B-5.63
Sagimet Biosciences Inc. (SGMT)United States$0.279B
Prelude Therapeutics Inc (PRLD)United States$0.318B-7.01